Professor Michael Barry:

The Senator is right that there are certain differences between the drugs and differences in the evidence and so on. I do not see why we would not look at that area, but it is only fair to say the discussion on early access in relation to cancer is just recent. The Senator might argue it should have been long before now, but that is where we are at.